NVHR in the News
2020 News Stories
We Can’t Eliminate Hepatitis C Without Removing Barriers to Treatment - Nov. 14, 2020
To progress toward eliminating this disabling and deadly disease, the U.S. must eliminate Medicaid restrictions on hepatitis C treatment and educate providers about ongoing stigma that disenfranchises certain communities.
State Policies Create Barriers to Hepatitis C Elimination - Nov. 13, 2020
Requiring sobriety prior to treatment and curtailing harm reduction hinder efforts to eliminate hep C.
Consider the Unintended Consequences on Patient Care - Oct. 15, 2020
NVHR's Adrienne Simmons was published in Hep Magazine advocating for CMS to delay a proposed Medicaid rule change that could negatively impact hepatitis patients.
New State Regulations Expand Access to Hepatitis C Treatments - Oct. 8, 2020
Dr. Adrienne Simmons, Pharmacist and Policy Manager at the National Viral Hepatitis Roundtable and Annette Gaudino, Director of Policy Strategy at the Treatment Action Group speak with WCNY's Capitol Pressroom about the removal of prior authorization requirements for hepatitis C treatment for NY Medicaid beneficiaries. Listen here.
NVHR and HEP Statement on Systemic Racism and Inequalities Facing Black Communities - June 3, 2020
Opinion: Hepatitis C is a curable disease. Texans shouldn’t have to wait for a cure Statesmen, March 7, 2020
2016
“It's Destroyed People's Lives”: The Shocking Rise in Hepatitis C-Related Deaths, Broadly, June 16, 2016
Report: Number of hepatitis C-linked deaths at record high, Pocono Record, May 18, 2016
It’s Time to End Insurance Restrictions on Life-Saving Hepatitis C Treatments, American Journal of Managed Care, May 3, 2016
Hepatitis C drug costs leave many without care, Boston Globe, April 9, 2016
The Link Between Hepatitis B, C, and Cancer, MediaPlanet, March 29, 2015
President's federal budget sustains HIV funding, viral hepatitis funding falls flat, The Bay Area Reporter, February 18, 2016
2015
State Medicaid Restrictions for Hepatitis C Cures Are Creating One of America's Worst Health Disparities, Huffington Post, December 11, 2015
Gilead expands PrEP assistance; feds call for more hep C coverage, The Bay Area Reporter, November 26, 2015
Hep C: Why doctors say all baby boomers should be tested, Chicago Tribune, October 8, 2015
White House Is Pressed to Help Widen Access to Hepatitis C Drugs via Medicaid, The New York Times, August 25, 2015
A Time to Cure: The Growing Case for New Hepatitis C Treatments, Huffington Post, August 13, 2015
The Past, Present and Future of Hepatitis C, USA Today, September 23, 2015
Discourse needed on 'culturally invisible' disease, Bloomington Herald-Times, August 19, 2015
Specialty Drug Costs: Hard Pills to Swallow, Workforce, May 24, 2015
Resolved For 2015: No More Hepatitis C, Huffington Post, January 8, 2015
2014
One company’s battle to stop the wave of high-priced drugs, The Washington Post, December 24, 2014
Hepatitis C: The cost conundrum, The Hill, November 12, 2014
Hepatitis C patients may not qualify for pricey drugs unless illness is advanced, The Washington Post, November 4, 2014
Some Hep C Patients May Not Get Coverage for Pricey Drugs, MedPage Today, October 28, 2014
Harvoni, a Hepatitis C Drug From Gilead, Wins F.D.A. Approval, New York Times, October 10, 2014
Why Hepatitis C Still Kills 16,000 Americans Per Year, and What We Can Do About It, Huffington Post, July 28, 2014
States limit Medicaid users’ access to hepatitis drug because of cost, Delaware Online, July 28, 2014
Sovaldi Debate Continues: Will Medicaid And Insurance Companies Approve This High Cost Cure For Hepatitis C Patients?,Medical Daily, July 24, 2014
Patient Cures Spur Demand for $1,000 Hepatitis C Pill, Bloomberg, July 24, 2014
New hepatitis C drugs’ price prompts an ethical debate: Who deserves to get them?, The Washington Post, May 2, 2014
Medicare Eases Restrictions On Pricey Hepatitis C Treatment, NPR, May 16, 2014
Medicare Won't Always Pay For Boomers' Pricey Hepatitis C Drugs, NPR, May 12, 2014
Healthier Patients May Have To Wait For Costly Hepatitis C Drugs, NPR, May 12, 2014
Costly hepatitis C drug worries insurers, patients, Tampa Bay Times, March 23, 2014
